## ILMN: Illumina, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.62 indicates fundamental undervaluation. Quality metrics strong (ROE 31%). Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($126.66)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. United States DNA Sequencing Market 2031 | Growth Drivers, Key Players & Investment Opportunities | Leading Companies - Bio-Rad Laboratories Inc., Danaher Corporation, Eurofins Scientific, F. Hoffmann-La Roche, Illumina Inc.**
- Source: openPR.com | 20251215T120923 | Bullish | Relevance: 100%
- The United States DNA Sequencing Market is expected to grow at a CAGR of 11.3% during the forecast period (2024-2031). Recent developments include Illumina's collaboration with MyOme and acquisition of SomaLogic, and Pacific Biosciences' updates to its Revio sequencing system, all aimed at advancing genomic applications and personalized medicine. Key market players include Illumina Inc., Danaher Corporation, and Thermo Fisher Scientific Inc., with North America holding the largest market share due to its advanced healthcare infrastructure and genomics research funding.

**2. Nikko Asset Management Americas Inc. Increases Stake in Illumina, Inc. $ILMN**
- Source: MarketBeat | 20251214T110910 | Somewhat-Bullish | Relevance: 100%
- Nikko Asset Management Americas Inc. significantly increased its stake in Illumina, Inc. ($ILMN) by 28.8% in Q2, bringing its total holdings to 867,981 shares valued at approximately $82.8 million. Other institutional investors also raised their positions, leading to an overall institutional ownership of 89.42%. Despite a "Hold" consensus rating from Wall Street and an average price target of $115, Illumina exceeded its latest quarterly EPS and revenue estimates and provided positive FY2025 guidance.

**3. Ieq Capital LLC Buys 176,611 Shares of Illumina, Inc. $ILMN**
- Source: MarketBeat | 20251213T070910 | Somewhat-Bullish | Relevance: 100%
- Ieq Capital LLC significantly increased its stake in Illumina, Inc. (NASDAQ:ILMN) by 256.7%, adding 176,611 shares in the second quarter, bringing its total holdings to 245,409 shares valued at $23.41 million. Other institutional investors also raised their positions, contributing to an overall institutional ownership of 89.42%. Analysts maintain a consensus "Hold" rating with a $115 price target, while Illumina recently surpassed EPS estimates and provided positive FY2025 guidance.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Barclays | $110 | $100 | +10% |
| 2025-12-15 | JP Morgan | $130 | $105 | +24% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Barclays | main | Underweight |
| 2025-12-15 | JP Morgan | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.09M) |
| Sells | 10 ($80.38M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Capital World Invest: 13.1% (+20.0%)
- Blackrock Inc.: 12.2% (-3.5%)
- Vanguard Group Inc: 9.6% (-3.5%)
- State Street Corpora: 3.9% (+6.8%)
- Sessa Capital IM, L.: 3.1% (-0.8%)

### Key Risks

1. Heavy insider selling: $80M sold (10 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_20 improving +2.4% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.62 indicates undervaluation relative to growth. Forward P/E 27.0x stretched relative to 6% growth. Quality metrics strong (ROE 31%, margin 16%). Analyst sentiment positive (2 raises, avg +17%). Insider selling cluster ($80.4M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.7B |
| Beta | 1.44 |
| 52W Range | $68.70 - $153.06 |
| Short Interest | 7.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.62 |
| Forward P/E | 27.0 |
| Current P/E | 28.6 |
| YoY Growth | 6.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 3.1% to 5.5% (+2.4% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 78th percentile. MRS_5 at 1.7% confirms short-term momentum alignment. AM_20 at 5.2% shows strong absolute momentum above own 20MA. Outperforming sector by 4.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +DBN (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 5.55% (CS: 78) | Strong |
| RSI_14 | 68.5 | Neutral |
| MACD Histogram | -0.00 | Bearish |
| vs SMA20 | 1.052x | Above |
| vs SMA50 | 1.175x | Above |
| vs SMA200 | 1.405x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $134.92
- **Stop Loss:** $126.66 (6.1% risk)
- **Target:** $151.44 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 145
- **Position Value:** $19,563.40
- **Portfolio %:** 19.56%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-05 (Est: $1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.17 | $1.34 | +14.7% |
| 2025Q2 | $1.01 | $1.19 | +17.7% |
| 2025Q1 | $0.94 | $0.97 | +3.3% |
| 2024Q4 | $0.92 | $0.86 | -6.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*